Abstract
In recent years the anti-CD19/anti-CD3 bispecific antibody blinatumomab and chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown early efficacy in clinical trials of paediatric and adult B-cell precursor acute lymphoblastic leukaemia (BCP-ALL).1, 2, 3, 4, 5 The rationale behind targeting CD19 in BCP-ALL is primarily its homogenous cell surface expression and B-lineage specificity.5 Thus, the entire malignant cell population should be targeted and eradicated by anti-CD19-directed immunotherapies. CD19 would be expected to have important functions in BCP-ALL survival, based on its roles in enhancing pre-B-cell receptor (pre-BCR) mediated phosphoinositide 3-kinase (PI3K) signalling and through pre-BCR-independent pathways such as MYC activation.6, 7, 8, 9 However, the effects of CD19 depletion on BCP-ALL cells have not been investigated. Hence, we examined the role of CD19 in leukaemic maintenance by silencing its expression in BCP-ALL cell lines and primograft samples using RNA interference.
Highlights
In recent years the anti-CD19/anti-CD3 bispecific antibody blinatumomab and chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown early efficacy in clinical trials of paediatric and adult B-cell precursor acute lymphoblastic leukaemia (BCP-ALL).[1,2,3,4,5] The rationale behind targeting CD19 in BCP-ALL is primarily its homogenous cell surface expression and B-lineage specificity.[5]
We examined the role of CD19 in leukaemic maintenance by silencing its expression in BCP-ALL cell lines and primograft samples using RNA interference
We explored the effects of CD19 knockdown in CD19+ BCPALL cell lines reflecting three maturation stages of BCP-ALL: pro-BALL SEM (CD10−CD19+), common B-ALL REH (CD10+CD19+) and pre-B-ALL 697 (CD10+CD19+cyIgM+)
Summary
In recent years the anti-CD19/anti-CD3 bispecific antibody blinatumomab and chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown early efficacy in clinical trials of paediatric and adult B-cell precursor acute lymphoblastic leukaemia (BCP-ALL).[1,2,3,4,5] The rationale behind targeting CD19 in BCP-ALL is primarily its homogenous cell surface expression and B-lineage specificity.[5]. BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance We examined the role of CD19 in leukaemic maintenance by silencing its expression in BCP-ALL cell lines and primograft samples using RNA interference.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
